Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-03-07-Speech-1-203-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-03-07"^^xsd:date2
dcterms:Is Part Of	lp_eu:Management of H1N1 influenza (short presentation)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20110307.23.1-203-000"2
lpv:hasSubsequent	lp_eu:2011-03-07-Speech-1-204-0002
lpv:speaker	lp:Jolanta Emilia Hibner2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2011-07-03)3 substitute; ITRE (2009-07-16--2012-01-18)3 substitute; Delegation for relations with Switzerland and Norway and to the EU-Iceland Joint Parliamentary Committee and the European Economic Area (EEA) Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; Delegation to the EU-Moldova Parliamentary Cooperation Committee (2009-09-15--2011-07-03)3 unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3
lpv:translated text	"When it comes to the assessment of epidemiological risks, one should use the knowledge of independent experts who are not affiliated with pharmaceutical companies. The independence of the European Union in assessing the severity of AH1N1 influenza and the resulting risk is crucial. We must not rely solely on studies of experts funded by pharmaceutical companies. Another puzzling aspect is the fast-track procedure used to introduce vaccines against H1N1, which had not been sufficiently tested and examined, to the market. In 2009, the pharmaceutical companies assessed the risk associated with the virus as very high, while it turned out to be less dangerous than ordinary flu. Back in May 2009, the WHO reported that the virus was not that dangerous. However, due to conflicting information, many countries gave in to the pressure and bought millions of expensive vaccines, which have not been used, and have by now become unusable. There is a need for a greater transparency of EU institutions in the field of disease management and a review of existing procedures. Greater and closer cooperation between countries is also essential to strengthen our negotiating position with regard to vaccine purchases. I would like to mention that my home country, Poland, has set an example from the very beginning of how not to succumb to panic and how to demand a guarantee of the vaccines’ safety."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph